Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2020-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
2020年_半年度报告_合并报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "益丰大药房连锁股份有限公司 2020 年半年度报告" which translates to "Yifeng Pharmacy Chain Co., Ltd. 2020 Semi-Annual Report." It explicitly states it is a half-year report covering the period from January 1, 2020 to June 30, 2020. The content includes detailed financial data, business overview, management discussion, and analysis typical of an interim or quarterly report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2020 年半年度报告摘要" which translates to "2020 Half-Year Report Summary." It contains detailed financial data for the first half of 2020, including total assets, net profit, revenue, and operational metrics. The document discusses business operations, store network, and financial performance for the half-year period ending June 30, 2020. It explicitly states it is a half-year report summary derived from the full half-year report and includes substantive financial data and analysis. The length of the document (5581 characters) and the detailed financial and operational data confirm it is a comprehensive interim report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
第三届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Yifeng Pharmacy Chain Co., Ltd. It includes details about the meeting date, attendance, and voting results on several agenda items, such as approval of the 2020 semi-annual report and a special report on the use of raised funds, as well as a financing-related proposal. The document does not contain the actual semi-annual report or financial statements but refers readers to the Shanghai Stock Exchange website for the full reports. The document is primarily about board meeting decisions and disclosures related to management and governance activities, not the reports themselves. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1653 characters), and it is an announcement of board resolutions, not a full report or financial statement.
2020-08-27 Chinese
关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company 益丰大药房连锁股份有限公司 regarding the completion of industrial and commercial registration changes, including updates to the company's basic registration information such as name, type, address, legal representative, registered capital, and business scope. It is a formal disclosure about corporate registration details and does not contain financial statements, audit information, or report data. The document length is short (1289 characters) and it is clearly an announcement of a corporate change rather than a financial report or regulatory filing. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2020-08-04 Chinese
高级管理人员集中竞价减持股份结果公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the results of a share reduction by a senior management person (肖再祥) through centralized bidding. It details the number of shares held before and after the reduction, the percentage of total shares, the period of the reduction, and the completion status. There is no financial report, earnings data, or regulatory certification. The content focuses on insider share transactions by a company executive. According to the filing definitions, this fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is short and specific to this insider transaction, confirming the classification.
2020-07-29 Chinese
关于使用部分闲置募集资金购买结构性存款产品到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Yifeng Pharmacy Chain Co., Ltd. regarding the use of idle raised funds to purchase structured deposit products and their redemption upon maturity. It details specific financial transactions related to cash management of idle raised funds, including amounts, dates, and returns. The document is relatively short (1969 characters) and focuses on the company's use of funds and related financial products, not on comprehensive financial statements or full financial performance. It is not an annual or interim report, nor an earnings release. It is a specific update on capital management activities related to fundraising proceeds. Therefore, it fits best under Capital/Financing Update (CAP).
2020-07-27 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.